Deals channel feed

All of the news, delivered with full-text to your inbox. For professionals discovering, developing, and marketing biopharmaceutical drugs.

Subscribe to Endpoints News

Velox­is wins $1.3B buy­out, and the new own­er plans to fol­low up with new deals

Japan’s Asahi Kasei Pharma has stepped up with a deal to buy out Copenhagen-based Veloxis Pharmaceuticals for $1.3 billion, bagging an organ rejection drug in the process.

The deal comes 17 years after Veloxis was founded, and the two big shareholders — Novo Holdings and Lundbeckfond Invest — have both signed off on the buyout. The biotech makes an immunosuppressive drug called Envarsus XR for kidney transplants.

Mark Timney Purdue from Youtube

Ex-Pur­due CEO stands to earn a huge wind­fall in No­var­tis' buy­out of the Med­i­cines Co

Mark Timney, the ex-Purdue Pharma CEO named in dozens of lawsuits against the OxyContin maker, stands to earn over $85 million in Novartis’s $9.7 billion buyout of the Medicines Company.

Timney joined the Medicines Company as CEO in December, after four years helming the company broadly considered to be at the heart of the opioid abuse crisis. SEC filings from the time of his hire show he agreed to purchase $500,000 worth of stock at the time and was also granted one million performance and time-vested stock options.

‘Break­through’ blad­der can­cer drug spin­out gets $570M to back launch of a new gene ther­a­py in the US

With its BLA filed and under priority review at the FDA, Ferring is spinning out a gene therapy for bladder cancer into a new biotech starting out with $570 million in backing — much of it from Blackstone Life Sciences.

Ferring in-licensed nadofaragene firadenovec (rAd-IFN/Syn3) from the Finnish company FKD about 18 months ago. Now Blackstone is stepping up with $400 million in cash to back the up-to $170 million that Ferring is chipping in to create FerGene, which is being set up to commercialize the drug in the US.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 67,500+ biopharma pros reading Endpoints daily — and it's free.

Ac­quis­i­tive No­var­tis bags PC­SK9 play­er Med­Co for $9.7B, set­ting up a flank at­tack on Sanofi, Re­gen­eron and Am­gen

The rumors were true.

Novartis has struck a deal to buy the Medicines Company $MDCO for $9.7 billion, putting it in the driver’s seat of a new — and very late-stage — PCSK9 drug that has the Sanofi/Regeneron team as well as Amgen on high alert for some major league competition.

The deal weighs in at $85 a share, giving the biotech a “fully diluted equity value of approximately USD 7.7 billion when including the impact of outstanding stock options and convertible debt,” according to Novartis.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 67,500+ biopharma pros reading Endpoints daily — and it's free.

Team­ing up with NIH, Vi­iV buys in­to the next big thing in HIV: an­ti­bod­ies

Weeks after taking over from John Pottage, Kim Smith — ViiV Healthcare’s newly minted head of R&D — has found a new HIV treatment approach to champion and do some heavy lifting around.

The GSK subsidiary has licensed a “broadly neutralizing antibody” from the NIH that promises to recognize and block the entry of multiple HIV strains into healthy CD4+ T cells. By binding to a specific site known as gp120 on the surface of the virus, N6LS is engineered to keep them out and annul any chance of replication inside cells — which can work as either prophylaxis or therapy.

Ahead of strate­gic up­date, new Sanofi CEO mulls op­tions for con­sumer health­care arm — re­ports

Big pharma has made moves to sharpen its focus on developing new medicines, while slow-growing consumer health divisions fall by the wayside. Looks like another large drugmaker is considering a similar move. On Thursday, reports citing sources indicated that Sanofi is reportedly mulling a joint venture, sale, or a public listing of its consumer health arm.

The French group is in discussions for options that could value the division at $30 billion, Bloomberg and Reuters reported, citing sources familiar with the matter.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 67,500+ biopharma pros reading Endpoints daily — and it's free.

Brii Bio backs in­fec­tious dis­ease start­up while ink­ing deal for its lead TB drug, dou­bling down on an­tibi­otics

Almost two years after leaving GSK to launch Brii Bio with a whopping $260 million in funding, Zhi Hong is seeing the trans-Pacific infectious disease specialist he set out to build take shape.

“Our pipeline is coming together,” he told Endpoints News, with 12 partnered assets plus some internal programs.

As its latest partner, AN2 Therapeutics, comes into the limelight for the first time with a $12 million seed round, so is Brii’s plans in the antibiotics space. Brii has obtained China rights to AN2’s antibacterial targeting mycobacterium tuberculosis for multi-drug resistant TB, which it says is in the clinical stage.

Ab­b­Vie scoops up op­tion to li­cense Har­poon's BC­MA drug for $50M up­front as biotech part­ner preps PhI/II tri­al

AbbVie is arming itself with another set of bow and arrows to shoot at BCMA in multiple myeloma — and this time it has turned to collaborators at Harpoon Therapeutics.

In paying $50 million for an option to license HPN217, AbbVie gains exclusive access to a Tri-specific T cell Activating Construct, or TriTAC, that is being steered to a Phase I/II trial. The dosing of the first patient will call for another $50 million in contingent milestone payment. Once Harpoon comes up with the data, its pharma giant partner will decide whether to officially add it to the arsenal.

Dicer­na scores broad, 'rest of liv­er' deal with No­vo Nordisk, bag­ging $225M in cash to hit some 30 tar­gets with RNAi plat­form

Turns out Dicerna wasn’t done with deals yet after locking in $200 million upfront from Roche for a hepatitis B cocktail two weeks ago.

Novo Nordisk has signed on as the latest partner to its GalXC RNAi platform, handing over $175 million in cash to claim any and all targets of interest in liver-related cardio-metabolic diseases that are not already reserved in previous pacts. The Danish drugmaker — which has signaled its interest to expand considerably beyond its core diabetes franchise into areas like NASH — is also purchasing $50 million worth of Dicerna’s equity at a 25% premium of $21.93 per share. More research payments and milestones extending to the billions are on the line.

Dutch di­ag­nos­tics play­er Qi­a­gen con­firms buy­out talks fol­low­ing re­port of Ther­mo Fish­er's in­ter­est

Several bidders have laid their eyes on Dutch diagnostics firm Qiagen — and Thermo Fisher is reportedly one of them.

Qiagen, which is listed on the NYSE, notified investors on Friday that “it has begun a review of potential strategic alternatives after receiving several conditional, non-binding indications of interest for the acquisition of all issued and outstanding shares of the Company.” It didn’t name any of the potential buyers.